- Home
- VKTX vs IMVT Comparison
VKTX vs IMVT Comparison
Compare VKTX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- IMVT
- Stock Information
- Founded
- VKTX 2012
- IMVT 2018
- Country
- VKTX United States
- IMVT United States
- Employees
- VKTX N/A
- IMVT N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VKTX Health Care
- IMVT Health Care
- Exchange
- VKTX Nasdaq
- IMVT Nasdaq
- Market Cap
- VKTX 3.0B
- IMVT 2.7B
- IPO Year
- VKTX 2015
- IMVT N/A
- Fundamental
- Price
- VKTX $33.65
- IMVT $16.61
- Analyst Decision
- VKTX Strong Buy
- IMVT Buy
- Analyst Count
- VKTX 12
- IMVT 10
- Target Price
- VKTX $86.42
- IMVT $33.38
- AVG Volume (30 Days)
- VKTX 5.3M
- IMVT 1.7M
- Earning Date
- VKTX 10-22-2025
- IMVT 11-06-2025
- Dividend Yield
- VKTX N/A
- IMVT N/A
- EPS Growth
- VKTX N/A
- IMVT N/A
- EPS
- VKTX N/A
- IMVT N/A
- Revenue
- VKTX N/A
- IMVT N/A
- Revenue This Year
- VKTX N/A
- IMVT N/A
- Revenue Next Year
- VKTX N/A
- IMVT N/A
- P/E Ratio
- VKTX N/A
- IMVT N/A
- Revenue Growth
- VKTX N/A
- IMVT N/A
- 52 Week Low
- VKTX $18.92
- IMVT $12.72
- 52 Week High
- VKTX $81.73
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- VKTX 62.67
- IMVT 51.86
- Support Level
- VKTX $25.04
- IMVT $15.95
- Resistance Level
- VKTX $32.85
- IMVT $17.15
- Average True Range (ATR)
- VKTX 1.49
- IMVT 0.72
- MACD
- VKTX 1.01
- IMVT 0.07
- Stochastic Oscillator
- VKTX 88.54
- IMVT 62.65
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.